Skip to Content

Product Information Update – Chloromycetin Redidrops Eye Drops (Chloramphenicol)

19/09/2022
Medicines for human use Product information update (PIU)

Latest communication - 15 September 2022

The HPRA would like to highlight a letter issued to healthcare professionals by Advanz Pharma on 15 September 2022.

The letter communicates that the product information has been further updated with recommendations for use in children. There has been a Change from ‘Contraindication’ to ‘Prescribe with Caution’ for children under 2 years.

Please download the letter using the link below. Please note that this letter supersedes previous letters issued to healthcare professionals on this product (October 2020, June 2021). 

Previous Product Information Updates on this product

Please note the two communications below are now superseded by the communication published on 15 September. 

  • Letter re-published on the HPRA website in June 2021 - now superceded by the communication dated September 2022
  • Letter published on the HPRA website in October 2020 - now superceded by the communication dated September 2022

Product information

Active substance
Chloramphenicol
Authorisation holder
Amdipharm Limited
Authorisation number
PA1142/021/001
Human or veterinary medicine
Human Medicine

Documents

Opens in new window Chloromycetin Redidrops Eye Drops (Chloramphenicol) - Product Information Update - September 2022 PDF : 627KB | 11/02/2025 Opens in new window Chloromycetin Redidrops Eye Drops (Chloramphenicol) - Product Information Update - June 2021 PDF : 508KB | 11/02/2025 Opens in new window Chloromycetin Redidrops Eye Drops (Chloramphenicol) - Product Information Update - October 2020 PDF : 520KB | 11/02/2025